Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) have been given an average recommendation of "Buy" by the six research firms that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $132.67.

Several equities research analysts have issued reports on the company. B. Riley lowered their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Truist Financial lowered their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th.

Insider Transactions at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock valued at $6,016,046 over the last three months. Company insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. State of Michigan Retirement System boosted its position in Lantheus by 0.6% during the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock valued at $1,620,000 after purchasing an additional 100 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its position in Lantheus by 0.4% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock valued at $2,364,000 after purchasing an additional 115 shares during the last quarter. Signaturefd LLC boosted its position in Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 116 shares during the last quarter. Intrust Bank NA boosted its position in Lantheus by 2.9% during the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider's stock valued at $431,000 after purchasing an additional 125 shares during the last quarter. Finally, Bleakley Financial Group LLC boosted its position in Lantheus by 6.1% during the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock valued at $200,000 after purchasing an additional 129 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Up 1.8%

Shares of Lantheus stock opened at $81.24 on Monday. Lantheus has a 12 month low of $75.00 and a 12 month high of $126.89. The business has a fifty day simple moving average of $97.11 and a 200 day simple moving average of $93.08. The stock has a market cap of $5.62 billion, a PE ratio of 13.52 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same period last year, the firm earned $1.69 earnings per share. The firm's revenue for the quarter was up .8% on a year-over-year basis. Analysts expect that Lantheus will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.